Annovis Bio to Launch Open-Label Extension Study for Buntanetap in Parkinson Disease

Annovis Bio Inc. (NYSE: ANVS) announced it will initiate an open-label extension study in January 2026 to further evaluate the long-term safety and efficacy of buntanetap in patients with Parkinson disease. The study will provide continued access to buntanetap for participants from prior clinical trials while enabling extended monitoring of safety outcomes, sustained effects on motor and cognitive function, and the collection of biomarker data to support further evaluation of buntanetap's potential as a disease-modifying therapy for neurodegenerative disorders.

The announcement represents a significant step in the clinical development pathway for buntanetap, which targets multiple neurotoxic proteins implicated in neurodegeneration. By extending treatment access and data collection beyond initial trial phases, researchers can gather crucial evidence about whether the therapy can modify disease progression rather than merely manage symptoms. This distinction is particularly important for Parkinson disease, where current treatments primarily address symptom management rather than underlying disease mechanisms.

The open-label extension study design allows for continued evaluation of safety parameters over an extended period, addressing regulatory requirements for long-term drug safety profiles. Simultaneously, the sustained monitoring of motor and cognitive functions provides insights into whether therapeutic benefits persist or evolve with prolonged treatment. The collection of biomarker data represents another critical component, potentially offering objective measures of biological changes associated with treatment response and disease modification.

For patients with Parkinson disease, this development offers continued access to an investigational therapy that has shown promise in earlier clinical evaluations. The study's focus on both motor and cognitive functions addresses two primary domains affected by Parkinson disease, reflecting a comprehensive approach to treatment evaluation. As neurodegenerative diseases like Parkinson's and Alzheimer's represent growing public health challenges globally, advances in disease-modifying therapies could significantly impact patient care and healthcare systems.

The broader implications extend to the neurodegenerative disease research community, where successful demonstration of disease modification could validate novel therapeutic approaches targeting multiple neurotoxic proteins simultaneously. Annovis Bio's commitment to addressing neurodegeneration through innovative therapies aligns with increasing recognition that complex diseases may require multi-target interventions. Additional information about the company's research can be found at https://www.AnnovisBio.com.

Investors and stakeholders following developments in the biotechnology sector can access the latest news and updates relating to ANVS through specialized communications platforms focused on biomedical sciences. The original announcement was distributed through https://www.BioMedWire.com, a platform within the Dynamic Brand Portfolio that provides specialized coverage of biotechnology and life sciences developments. The full press release detailing this announcement is available at https://ibn.fm/MaSkN.

As the January 2026 study initiation approaches, the medical community will monitor how extended treatment with buntanetap affects long-term outcomes in Parkinson disease patients. The data generated could inform future clinical trial designs, regulatory submissions, and ultimately treatment paradigms for neurodegenerative disorders. With neurodegenerative diseases affecting millions worldwide and placing substantial burdens on healthcare systems and caregivers, advances in disease-modifying therapies represent important milestones in medical research and patient care.